VIBOSTOLIMAB PLUS PEMBROLIZUMAB WITH/WITHOUT DOCETAXEL VS DOCETAXEL IN NSCLC AFTER PLATINUM CHEMOTHERAPY AND IMMUNOTHERAPY

被引：0

作者：

Peters, Solange ^{[1
]}

Lee, Dae Ho ^{[2
]}

Ramlau, Rodryg ^{[3
]}

Halmos, Balazs ^{[4
]}

Schumann, Christian ^{[5
]}

Planchard, David ^{[6
]}

Bhagwati, Niyati ^{[7
]}

Chen, Diana ^{[7
]}

Kush, Debra ^{[7
]}

Novello, Silvia ^{[8
]}

机构：

[1] Univ Lausanne, Ctr Hosp Univ Vaudois, Lausanne, Switzerland

[2] Asan Med Ctr, Seoul, South Korea

[3] Poznan Univ Med Sci, Poznan, Poland

[4] Montefiore Einstein Ctr Canc Care, Dept Oncol, New York, NY USA

[5] Klin Pneumol Thoraxonkol Schlaf & Beatmungsmed, Klinikverbund Allgau, Kempten, Germany

[6] Dept Med Oncol, Thorac Grp, Gustave Roussy, Villejuif, France

[7] Merck & Co Inc, Kenilworth, NJ USA

[8] Gonzaga Univ Turin, Azienda Osped Univ San Luigi, Dept Oncol, Orbassano, Italy

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.463

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

463

引用

页码：A492 / A492

页数：1

共 50 条

[41] Ramucirumab plus Docetaxel (DOC) vs PBO plus DOC for Stage IV NSCLC after Disease Progression (REVEL): Indian Sub-Group Analysis
Prabhash, K.
Doval, D.
Rangarajan, B.
Somani, N.
Pruthi, A.
D'Yachova, Y.
Puri, T.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S246 - S246
[42] Switch maintenance therapy with racotumomab or nimotuzumab vs docetaxel for NSCLC patients
Hernandez, M.
Neninger, E.
Ortiz, R. A.
Camacho, K.
Amador, R. M.
Bello, L.
Flores, Y.
Acosta, S.
Pichs, G.
Cala, M.
Corella, M.
Jimenez, Y.
Diaz, Y.
Viada, C. E.
Robina, M.
Valdes, A.
Mendoza, I. C.
Guerra, P. P.
Macias, A.
Crombet, T.
ANNALS OF ONCOLOGY, 2016, 27
[43] Docetaxel and cisplatin as first-line chemotherapy in advanced NSCLC.
Behera, D
Aggarwal, AN
Gupta, D
Jindal, SK
Sharma, SC
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 705S - 705S
[44] A randomized phase II trial of anlotinib plus docetaxel vs docetaxel for second-line treatment of EGFR-negative NSCLC (ALTER-L018)
Wu, L.
Wu, Z.
Xiao, Z.
Ma, Z.
Weng, J.
Chen, Y.
Cao, Y.
Cao, P.
Xiao, M.
Zhang, H.
Duan, H.
Wang, Q.
Li, J.
Xu, Y.
Pu, X.
Li, K.
ANNALS OF ONCOLOGY, 2021, 32 : S970 - S970
[45] Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial
Wu, L.
Wu, Z.
Xiao, Z.
Ma, Z.
Weng, J.
Chen, Y.
Cao, Y.
Cao, P.
Xiao, M.
Zhang, H.
Duan, H.
Wang, Q.
Li, J.
Xu, Y.
Pu, X.
Li, K.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1105 - S1106
[46] Rate of neutropenic sepsis in relapsed NSCLC patients receiving docetaxel chemotherapy
Gyi, M. M.
Gulliford, T. J.
Muthuramalingam, S. R.
LUNG CANCER, 2017, 103 : S41 - S42
[47] Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized phase II trial.
Pectasides, D
Farmakis, D
Pectasides, M
Kostopoulou, V
Nikolaou, M
Koumpou, M
Gaglia, A
Kountourakis, P
Mylonakis, N
Economopoulos, T
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 625S - 625S
[48] COMPARISON OF DOCETAXEL AND PACLITAXEL FOR ADVANCED ESOPHAGEAL CANCER AFTER PROGRESSION ON PLATINUM-BASED CHEMOTHERAPY
Ohori, H.
Takahashi, Y.
Takahashi, M.
Gamoh, M.
ANNALS OF ONCOLOGY, 2013, 24
[49] Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer
Saeki T.
Takashima S.
Breast Cancer, 2004, 11 (2) : 116 - 120
[50] Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
Onaga, Ryutaro
Enokida, Tomohiro
Ito, Kazue
Ueda, Yuri
Okano, Susumu
Fujisawa, Takao
Wada, Akihisa
Sato, Masanobu
Tanaka, Hideki
Takeshita, Naohiro
Tanaka, Nobukazu
Hoshi, Yuta
Tahara, Makoto
FRONTIERS IN ONCOLOGY, 2023, 13

← 1 2 3 4 5 →